Contribution of spinal cord glial cells to L. amazonensis experimental infection-induced pain in BALB/c mice

Keyphrases

• Balb C Mice 100%
• Spinal Cord 100%
• Glial Cells 100%
• CX3CR1 100%
• Experimental Infection 100%
• Evoked Pain 100%
• Leishmania Amazonensis 100%
• Interleukin-1β 90%
• MRNA Expression 90%
• Paw Edema 60%
• Mechanical Hyperalgesia 50%
• Post-infection 40%
• Hyperalgesia 40%
• Microglia 30%
• Astrocytes 30%
• Iba1 30%
• Thermal Hyperalgesia 30%
• Protein Level 20%
• Activating Transcription Factor 3 (ATF3) 20%
• Intrathecal Drug Delivery 20%
• MPO Activity 20%
• Interleukin-1 Receptor Antagonist (IL-1Ra) 10%
• Etanercept 10%
• Neuroinflammation 10%
• Microglial Activation 10%
• Neutralizing Antibodies 10%
• Tumor-draining Lymph Nodes 10%
• Epidermis 10%
• Chemokines 10%
• Receptor 1 10%
• Skin Infection 10%
• Intrathecal 10%
• Targeted Treatment 10%
• Disease Course 10%
• Nave 10%
• Western Blot 10%
• Glial Cell Activation 10%
• Parasitic Infection 10%
• TNF Receptor 2 (TNFR2) 10%
• Leishmaniasis 10%
• Chronic Pain 10%
• Intrathecal Injection 10%
• Plantar 10%
• Blood Levels 10%
• Glial Activation 10%
• Pain Processing 10%
• Parasitism 10%
• Infected Mice 10%
• Parasite Burden 10%
• Peripheral Inflammation 10%
• Confocal Immunofluorescence 10%
• Minocycline 10%
• Time-course Analysis 10%
• Astrocyte Activation 10%
• Microglial Markers 10%
• Spinal Microglia 10%
• Astrocyte Marker 10%
• Pain Pathophysiology 10%
• Mecha 10%
• Iba-1 Protein 10%
• DRG Cells 10%
• Dermal Thickness 10%
• Spinal Astrocytes 10%

Medicine and Dentistry

• Microglia 100%
• Infection 100%
• Experimental Infection 100%
• Tumor Necrosis Factor 81%
• Interleukin 1 81%
• Messenger RNA 81%
• Astrocyte 54%
• Paw Edema 54%
• Mechanical Hyperalgesia 45%
• Paw 36%
• Hyperpathia 36%
• Thermal Hyperalgesia 27%
• Contralateral 18%
• Interleukin 1 Receptor Blocking Agent 9%
• Cytokine 9%
• Neuroinflammation 9%
• Receptor 9%
• Pathophysiology 9%
• Lymph Node 9%
• Immunofluorescence 9%
• Skin Infection 9%
• Western Blot 9%
• Histopathology 9%
• Tumor Necrosis Factor Receptor 2 9%
• Chemokine 9%
• Chronic Pain 9%
• Neutralizing Antibody 9%
• Etanercept 9%
• Intrathecal Drug Administration 9%
• Minocycline 9%
• Parasitic Disease 9%
• Intraplantar Drug Administration 9%
• Leishmania 9%
• Leishmaniasis 9%
• Parasite Load 9%
• Aminoadipic Acid 9%
• Diseases 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Infection 100%
• Bagg Albino Mouse 100%
• Experimental Infection 100%
• Tumor Necrosis Factor 75%
• Interleukin 1 75%
• Messenger RNA 75%
• Paw Edema 50%
• Mechanical Hyperalgesia 41%
• Intrathecal 33%
• Hyperalgesia 33%
• Thermal Hyperalgesia 25%
• Etanercept 8%
• Receptor 8%
• Neutralizing Antibody 8%
• Cytokine 8%
• Inflammation 8%
• Interleukin 1 Receptor Blocking Agent 8%
• Pathophysiology 8%
• Western Blot 8%
• Nervous System Inflammation 8%
• Tumor Necrosis Factor Receptor 2 8%
• Chronic Pain 8%
• Chemokine 8%
• Leishmaniasis 8%
• Skin Infection 8%
• Minocycline 8%
• Aminoadipic Acid 8%
• Leishmania amazonensis 8%
• Diseases 8%